FDA Approves First Gene Therapy to Restore Hearing in Children Born Deaf – Groundbreaking Treatment Available Free in the US

In a historic medical breakthrough, the U.S. Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), the first-ever gene therapy capable of restoring natural hearing in children born with genetic deafness. The landmark approval, announced April 28, 2026, marks an unprecedented era in treating congenital hearing loss.

A Medical First That Changes Lives Forever

For decades, children born deaf had only two options: hearing aids for mild cases or cochlear implants that require ongoing battery changes and technological maintenance. Today, that landscape has fundamentally changed.

Otarmeni represents the first medical therapy in human history that enables deaf children to hear naturally, providing 24/7 biological hearing restoration without reliance on external devices.

Understanding Otoferlin Deafness

Otoferlin deafness is a rare genetic condition affecting approximately 1-3% of all congenital hearing loss cases. It's caused by mutations in the OTOF gene, which encodes otoferlin—a critical protein expressed in inner hair cells of the cochlea.

The cochlea, a fluid-filled spiral structure in the inner ear, converts mechanical vibrations from sound waves into electrical signals that travel to the brain through the auditory nerve. Otoferlin plays an essential role in this process by enabling the release of neurotransmitters that generate nerve impulses needed for sound perception.

When otoferlin is absent due to genetic mutations, children can be born profoundly deaf despite having otherwise normal ear structure and function.

The Groundbreaking CHORD Clinical Trial Results

The FDA approval followed extraordinary results from the CHORD registration trial, published in the New England Journal of Medicine:

• 80% of participants achieved hearing levels that met or surpassed the study's primary endpoint
• 42% achieved normal hearing, including the ability to hear whispers
• Before treatment, these individuals could not hear a gas-powered lawnmower (approximately 90 dB)
• 11 of 12 recipients (aged 10 months to 16 years) showed clinically meaningful responses

"After 48 weeks' follow-up, 5 attained normal hearing and another 5 were able to hear speech at typical conversational levels," reported Dr. Lawrence Lustig of Columbia University Irving Medical Center, a clinical investigator on the trial.

How Otarmeni Works: A Dual Vector Gene Therapy

Otarmeni addresses a unique scientific challenge: the OTOF gene is too large to package into standard adeno-associated virus (AAV) vectors used in most gene therapies.

The innovative solution: Otarmeni delivers two DNA fragments packaged into a dual hybrid AAV system. Following recombination inside target cells, these fragments encode the complete cDNA of the full-length otoferlin protein. The transgene operates under control of a synthetic promoter that restricts expression specifically to inner hair cells in the cochlea.

This precision targeting ensures the therapy affects only the cells responsible for hearing while leaving all other ear development and function intact.

Unprecedented Access: Free Treatment for All Eligible U.S. Patients

In an extraordinary move, Regeneron has committed to providing Otarmeni at no cost to all clinically eligible individuals in the United States. This decision addresses a critical concern with many gene therapies priced in the millions of dollars that achieve limited patient access.

"We wanted to make a statement," said Dr. George Yancopoulos, Regeneron's co-founder and chief scientific officer. "We want to be sure this treatment would be able to reach its full potential and help as many people as possible."

The company also announced alignment of Medicaid pricing for certain products with prices set in developed countries, further expanding accessibility.

Life-Changing Results: Real Stories from Trial Participants

The clinical trial produced emotional breakthroughs that scientists describe as unprecedented:

Travis Smith, now 2 years old, was one of the first children treated. His mother Sierra shared with CBS Mornings: "He didn't know his name. He couldn't hear me tell him how much I love him. And now with this amazing surgery, he can listen to music. He loves it and he loves to dance."

Another participant's mother, Kerri, told CNN: "You go from being told your child's profoundly deaf and may only ever hear with technology to your child hearing right alongside his friends. This is just amazing."

Dr. Eliot Shearer of Boston Children's Hospital, principal investigator on the trial, witnessed these transformations firsthand: "I've witnessed my trial participant responding to their mother's voice, dancing to music and interacting with the world. These moments are now possible for more children born with this specific form of hearing loss."

Expert Reactions: A New Era in Hearing Restoration

The medical community has responded with overwhelming enthusiasm:

Dr. Dylan Chan, pediatric otolaryngologist at UCSF, told The New York Times: "This is groundbreaking... This is the first time in history that there has been a medical therapy that has enabled deaf children to hear."

Dr. Daniel Lee, director of pediatric otology at Massachusetts Eye and Ear Infirmary, added: "We have now entered the era of biological treatment for inner ear hearing loss."

Professor Zheng-Yi Chen from the same institution told NPR: "It's the first time in history there's a new drug for hearing loss. I think it's an historical event, a landmark, a great development for the whole field."

The Fastest BLA Approval in Modern FDA History

The approval process itself set records. Otarmeni received accelerated review under the Commissioner's National Priority Voucher (CNPV) pilot program, with the FDA issuing approval just 61 days after Biologics License Application filing.

This marks:

• The sixth approval under the CNPV program
• The first gene therapy approved through this pathway
• Tied for the fastest BLA approval in modern FDA history

Dr. Leonard Schleifer, Regeneron's CEO, told CNBC: "I guarantee you they're not lowering standards. They're keeping the standards high, but this program says if there's an important program, let's move it along fast."

Beyond OTOF: The Future of Hearing Loss Gene Therapies

While otoferlin-mutation-associated hearing loss accounts for just 1-3% of congenital cases, researchers are already working on therapies targeting other genetic causes.

Regeneron is developing additional programs, including one targeting GJB2, which encodes connexin 26 (gap junction-β2 protein). This mutation is associated with the most prevalent form of congenital hearing loss.

Other companies advancing similar AAV-based therapies include:

• Akouos (Lilly subsidiary)
• Sensorion (Montpellier, France)
• Otovia Therapeutics (Shanghai)
• Seamless Therapeutics (partnered with Eli Lilly for $1.12 billion)

Universal Genetic Testing: A Potential New Standard?

Currently, genetic testing for congenital hearing loss is not routine in the United States. Dr. Lustig believes Otarmeni may change this paradigm entirely: "I believe Otarmeni will usher in universal genetic testing for all newborns diagnosed with some form of hearing loss."

This would have profound downstream consequences, opening possibilities for early intervention and long-term outcomes research into different types of genetic hearing loss.

Comparison to Existing Treatments

Cochlear Implants

• Invasive surgical procedure requiring implantation of electrode array
• Requires ongoing battery changes and external processor maintenance
• Limited by device technology, not biological restoration
• Cost: $30,000-$100,000+ per ear

Otarmeni Gene Therapy

• Single-time treatment with potential for permanent restoration
• Biological hearing restoration—natural 24/7 function
• No external devices or batteries required
• Provided free to eligible U.S. patients

Who Is Eligible for Otarmeni?

Based on FDA labeling, Otarmeni is indicated for:

• Pediatric and adult patients with severe-to-profound sensorineural hearing loss
• Any frequency greater than 90 dB HL
• Molecularly confirmed biallelic variants in the OTOF gene
• Preserved outer hair cell function
• No prior cochlear implant in the same ear

Genetic testing is required to confirm eligibility. The surgical procedure uses an approach similar to cochlear implantation and can be performed on young infants.

Regulatory Milestone for Gene Therapy

The Otarmeni approval represents more than just a hearing loss treatment—it demonstrates the potential of the FDA's priority review pathways for transformative therapies.

"The commissioner's voucher program says if there's an important program, let's move it along fast," noted Dr. Schleifer. "Everybody came together on this one: our scientists, the patients, the doctors, the FDA."

What This Means for Families

For families affected by genetic hearing loss, Otarmeni offers hope that was unimaginable just a decade ago.

"It's not like a little incremental change," said Dr. Shearer. "It's completely life-changing."

The therapy enables:

• Natural hearing development in young children during critical language acquisition periods
• 24/7 hearing without device maintenance or battery concerns
• Potential for normal speech and language development
• Social integration with peers who also hear naturally

Looking Ahead: Clinical Trial Access

While the FDA approval opens the door for broader treatment access, families interested in clinical trials or treatment should consult with otolaryngologists specializing in genetic hearing loss.

The National Institutes of Health maintains clinical trial information at ClinicalTrials.gov, where ongoing studies related to gene therapy for hearing loss can be identified.

References

1. U.S. Department of Health and Human Services. (2026). WTAS: FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. https://www.hhs.gov/press-room/wtas-fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher-program.html

2. Sheridan, C. (2026). Historic FDA approval brings first gene therapy for genetic deafness. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03145-w

3. Kolata, G. (2026). New Gene Therapy Enables Children With a Rare Form of Deafness to Hear. The New York Times. https://www.nytimes.com/2026/04/23/science/deaf-gene-therapy.html

4. Regeneron Pharmaceuticals, Inc. (2026). OtarmeniTM (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss. https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only

5. Lustig, L. A., et al. (2026). Gene therapy for otoferlin-deficient hearing loss: Interim analysis of the CHORD trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2400521

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Gene therapy for hearing loss is a specialized treatment requiring evaluation by qualified healthcare professionals. Consult with an otolaryngologist or genetic counselor to determine if Otarmeni may be appropriate for your specific situation. Treatment availability, eligibility criteria, and regulatory status may change. Always rely on guidance from licensed medical providers for health decisions.